INO Inovio Pharmaceuticals Inc.

Inovio Announces Initiation of “MD Anderson’s HPV-Related Cancers Moon Shot” Phase 2 Trial in New HPV Indications

Inovio Announces Initiation of “MD Anderson’s HPV-Related Cancers Moon Shot” Phase 2 Trial in New HPV Indications

Phase 2 cancer study will evaluate T cell-activating immunotherapy MEDI0457 with MedImmune’s durvalumab targeting several HPV-related cancers

PLYMOUTH MEETING, Pa., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the dosing of the first patient in a Phase 2 combination trial to evaluate MedImmune’s MEDI0457 (formerly called INO-3112 which MedImmune in-licensed from Inovio) in combination with durvalumab targeting a broad array of cancers associated with the human papilloma virus (HPV).

This open-label trial funded by MedImmune, the global biologics research and development arm of AstraZeneca, is sponsored by noted cancer researcher Dr. Michael Frumovitz, MD, MPH, of the MD Anderson Cancer Center in Houston, Texas, where the trial will be conducted as part of MD Anderson’s “Moon Shot” cancer initiative. MedImmune is evaluating MEDI0457 in combination with durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in patients with HPV-associated cervical, anal, penile, and vulvar cancers in arms of a clinical trial with an estimated total enrollment of 77 patients. For additional information about the study, please visit  (search identifier NCT03439085).

The opening of this trial will result in a milestone payment from MedImmune to Inovio. Financial arrangements were not disclosed.

Dr. Frumovitz said, “This is the first Phase 2 clinical trial at MD Anderson that is focused not on the site of disease origin, but instead on the cause of a cancer -- in this case exposure to HPV 16 or 18. The HPV Moon Shot at MD Anderson has developed an entire research program with this philosophy in mind — that HPV-associated cancers behave similarly, regardless of site of origin, and should be studied as a whole, not as individual cancers. This study will be “site agnostic”, meaning any patient with an HPV 16/18 associated cancer, regardless of primary site, will be eligible. Another truly unique aspect of this study is a separate cohort for patients who are HIV positive with an HPV 16/18 associated cancer.”

Dr. J. Joseph Kim, Inovio’s President and Chief Executive Officer, said, “We are pleased to see Inovio’s cancer-fighting immunotherapy, in MEDI0457, expand to new cancer indications. Such expansion is great for patients and the oncology community. For Inovio, amplification of HPV cancer targets holds the potential to bring about additional milestone and royalty payments.”

An article in the online edition of highlights a recent Phase 1 study of MEDI0457 as a monotherapy in 22 HPV-positive patients with HPV-associated head and neck cancer that demonstrated MEDI0457 generated robust HPV16/18 specific CD8+ T cell responses in peripheral blood and increased CD8+ T cell infiltration in resected tumor tissue. One patient in that trial who initially displayed a slight increase in T cell immune responses developed progressive disease at 11 months into the study and subsequently received a PD-1 checkpoint inhibitor. The patient achieved a complete response, which has sustained for over two years and counting. Increasing evidence suggests that response rates from checkpoint inhibitors can be enhanced when used in combination with cancer vaccines like MEDI0457 that generate tumor-specific T cells.

About MEDI0457 and VGX-3100

MEDI0457 (formerly called INO-3112 (VGX-3100, plus IL-12) which MedImmune in-licensed from Inovio) is under evaluation by MedImmune to treat HPV-associated cancers. Inovio is investigating VGX-3100, a DNA-based immunotherapy for the treatment of HPV-16 and HPV-18 infection and pre-cancerous lesions of the cervix (Phase 3) and vulva (Phase 2) and anal (Phase 2). VGX-3100 has the potential to be the first approved treatment for HPV infection of the cervix and the first non-surgical treatment for pre-cancerous cervical lesions. VGX-3100 works by stimulating a specific immune response to HPV-16 and HPV-18, which targets the infection and causes destruction of pre-cancerous cells. In a randomized, double-blind, placebo-controlled Phase 2b study in 167 adult women with histologically documented HPV-16/18 cervical HSIL (CIN2/3), treatment with VGX-3100 resulted in a statistically significantly greater decrease in cervical HSIL and clearance of HPV infection vs. placebo. The most common side effect was injection site pain, and no serious adverse events were reported. VGX-3100 utilizes the patient’s own immune system to clear HPV-16 and HPV-18 infection and pre-cancerous lesions without the increased risks associated with surgery, such as loss of reproductive health and negative psychosocial impacts.

Under the 2015 agreement, MedImmune acquired exclusive rights to Inovio's INO-3112, now called MEDI0457. MEDI0457 targets cancers caused by HPV types 16 and 18 which are responsible for more than 70 percent of cervical pre-cancers and cancers and are involved in the development of other tumors. Within the broader license and collaboration agreement, MedImmune and Inovio are co-developing one additional DNA-based cancer therapy product not included in Inovio's current product pipeline, which MedImmune has exclusive rights to develop and commercialize. Inovio will receive development, regulatory and commercialization milestone payments for these additional cancer vaccine products and will be eligible to receive royalties on worldwide net sales.

About Durvalumab

Durvalumab, a human monoclonal antibody directed against PD-L1, blocks PD-L1 interaction with PD-1 and CD80 on T cells, countering the tumor’s immune-evading tactics and inducing an immune response. As part of a broad development program, durvalumab is being investigated as monotherapy and in combination with IO, small molecules, and chemotherapies across a range of tumors and stages of disease.

About Inovio Pharmaceuticals, Inc.

Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA immunotherapies that transform the treatment of cancer and infectious diseases. Inovio’s proprietary platform technology applies next-generation antigen sequencing and DNA delivery to activate potent immune responses to targeted diseases. The technology functions exclusively in vivo, and has been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. Inovio is the only immunotherapy company that has reported generating T cells whose killing capacity correlates with relevant clinical outcomes. Inovio’s most advanced clinical program, VGX-3100, is in Phase 3 for the treatment of HPV-related cervical pre-cancer. Also in development are Phase 2 immuno-oncology programs targeting head and neck cancer, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV. Partners and collaborators include MedImmune, Regeneron, Roche/Genentech, ApolloBio Corporation, The Wistar Institute, University of Pennsylvania, Parker Institute for Cancer Immunotherapy, CEPI, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit .



This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs, including the planned initiation and conduct of clinical trials and the availability and timing of data from those trials, and our plans and expectations regarding partnerships. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2017, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 and other regulatory filings we make from time to time. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.

CONTACTS:                                                                                                                            

Investors: Ben Matone, Inovio, 484-362-0076,

Media: Jeff Richardson, Inovio, 267-440-4211,

EN
04/12/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Inovio Pharmaceuticals Inc.

 PRESS RELEASE

INOVIO Announces Notice of Pendency and Proposed Settlement of Stockho...

INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) -- INOVIO (NASDAQ:INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA: UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE INOVIO PHARMACEUTICALS, INC. DERIVATIVE LITIGATION Lead Case No. 2:20-cv-01962-GJP   NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE ACTIONS TO:        ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF...

INOVIO PHARMACEUTICALS sees a downgrade to Negative on account of less...

The independent financial analyst theScreener just lowered the general evaluation of INOVIO PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date March 15, 2022, the closing price was USD 3.14 and its target ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

W WAYFAIR INC.
DHR DANAHER CORPORATION
VEEV VEEVA SYSTEMS INC CLASS A
USNA USANA HEALTH SCIENCES INC.
TSCO TRACTOR SUPPLY COMPANY
TBPH THERAVANCE BIOPHARMA INC
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
SLP SIMULATIONS PLUS
SLGN SILGAN HOLDINGS INC.
SFM SPROUTS FARMERS MARKETS INC.
RRC RANGE RESOURCES CORPORATION
RGEN REPLIGEN CORPORATION
RARE ULTRAGENYX PHARMACEUTICAL INC.
PYPL PAYPAL HOLDINGS INC
OLLI OLLIE'S BARGAIN OUTLET HOLDINGS INC
NLS NAUTILUS INC
NGVC NATURAL GROCERS BY VITAMIN COTTAGE INC
MTRN MATERION CORPORATION
MSCI MSCI INC. CLASS A
MOH MOLINA HEALTHCARE INC.
MMSI MERIT MEDICAL SYSTEMS INC.
MKTX MARKETAXESS HOLDINGS INC.
LMNX LUMINEX CORP
LDOS LEIDOS HOLDINGS INC.
INO INOVIO PHARMACEUTICALS INC.
HALO HALOZYME THERAPEUTICS INC.
HAE HAEMONETICS CORPORATION
GFI GOLD FIELDS LTD. ADS
GBT GLOBAL BLOOD THERAPEUTICS INC
FOLD AMICUS THERAPEUTICS INC.
EBS EMERGENT BIOSOLUTIONS INC.
CONE CYRUSONE INC.
CNC CENTENE CORPORATION
CIEN CIENA CORPORATION
CERS CERUS CORP.
CALX CALIX NETWORKS
BMRN BIOMARIN PHARMACEUTICAL INC.
AU ANGLOGOLD ASHANTI LTD. ADS
ASC ARDMORE SHIPPING
ALXN ALEXION PHARMACEUTICALS INC.
ALNY ALNYLAM PHARMACEUTICALS INC
ALLT ALLOT LTD
AGI. ALAMOS GOLD INC.
AAWW ATLAS AIR WORLDWIDE HOLDINGS INC.
MRVL MARVELL TECHNOLOGY GROUP LTD.
IRBT IROBOT CORPORATION
CCO. CAMECO CORPORATION
AEM. AGNICO EAGLE MINES LIMITED
NAT NORDIC AMERICAN TANKERS LIMITED
ENTG ENTEGRIS INC.
KLAC KLA CORPORATION
WERN WERNER ENTERPRISES INC.
MTSI MACOM TECHNOLOGY SOLUTIONS HOLDINGS INC.
WMK WEIS MARKETS INC.
FIZZ NATIONAL BEVERAGE CORP.
INSG INSEEGO CORP
PHI PHILIPPINE LONG DISTANCE TELEPHONE COMPANY ADS
OKTA OKTA INC. CLASS A
ARNA ARENA PHARMACEUTICALS INC.
QTRX QUANTERIX CORPORATION
SE SEA ADS
AMD ADVANCED MICRO DEVICES INC.
SWCH SWITCH
VICR VICOR CORP.
ALLO ALLOGENE THERAPEUTICS
TBIO TRANSLATE BIO
MR MONTAGE RESOURCES CORP.
BYND BEYOND MEAT
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
CLVT CLARIVATE PLC (A)
ATEX ANTERIX INC
ARCT ARCTURUS THERAPEUTICS HOLDINGS INC
SQNS SEQUANS COMMUNICATIONS ADR
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets ar...

DXCM DEXCOM INC.
AMGN AMGEN INC.
TSFA TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD. SPONSORED ADR
DPZ DOMINO'S PIZZA INC.
LITE LUMENTUM HOLDINGS INC.
ITW ILLINOIS TOOL WORKS INC.
AMN AMN HEALTHCARE SERVICES INC.
NOW SERVICENOW INC.
MASI MASIMO CORPORATION
AAON AAON INC.
XLRN ACCELERON PHARMA INC
WST WEST PHARMACEUTICAL SERVICES INC.
WEC WEC ENERGY GROUP INC
VRTX VERTEX PHARMACEUTICALS INCORPORATED
VNET 21VIANET GROUP INC. SPONSORED ADR CLASS A
VIPS VIPSHOP HOLDINGS LTD SPONSORED ADR
TSLA TESLA INC
TMO THERMO FISHER SCIENTIFIC INC.
TDOC TELADOC HEALTH INC.
STMP STAMPS.COM INC.
SGEN SEAGEN INC.
SEDG SOLAREDGE TECHNOLOGIES INC.
RMD RESMED INC.
RGEN REPLIGEN CORPORATION
REGN REGENERON PHARMACEUTICALS INC.
QDEL QUIDEL CORPORATION
POWI POWER INTEGRATIONS INC.
PG PROCTER & GAMBLE COMPANY
NOVA NOVO NORDISK A/S ADS
NVDA NVIDIA CORPORATION
NEH NETEASE INC. SPONSORED ADR
MUSA MURPHY USA INC.
MNST MONSTER BEVERAGE CORPORATION
3KA STRIDE INC.
LMNX LUMINEX CORP
LLY ELI LILLY AND COMPANY
KR KROGER CO.
KMB KIMBERLY-CLARK CORPORATION
K KELLOGG COMPANY
JNJ JOHNSON & JOHNSON
JD JD.COM INC. SPONSORED ADR CLASS A
INO INOVIO PHARMACEUTICALS INC.
HRL HORMEL FOODS CORPORATION
HAIN HAIN CELESTIAL GROUP INC.
GIS GENERAL MILLS INC.
FLO FLOWERS FOODS INC.
EPZM EPIZYME INC.
N1U NEW ORIENTAL EDUCATION & TECHNOLOGY GROUP INC. SPONSORED ADR
EBS EMERGENT BIOSOLUTIONS INC.
DVA DAVITA INC.
DQ DAQO NEW ENERGY CORP SPONSORED ADR
CLX CLOROX COMPANY
CASY CASEY'S GENERAL STORES INC.
CALM CAL-MAINE FOODS INC.
BIIB BIOGEN INC.
A117ME ALIBABA GROUP HOLDING LTD. SPONSORED ADR
ALLT ALLOT LTD
AKAM AKAMAI TECHNOLOGIES INC.
ABC AMERISOURCEBERGEN CORPORATION
SCI SERVICE CORPORATION INTERNATIONAL
APS. APTOSE BIOSCIENCES
BIO BIO-RAD LABORATORIES INC. CLASS A
CCI CROWN CASTLE INTERNATIONAL CORP
ENPH ENPHASE ENERGY INC.
ZNGA ZYNGA INC. CLASS A
TR TOOTSIE ROLL INDUSTRIES INC.
EVBG EVERBRIDGE INC.
WDFC WD-40 COMPANY
ZTO ZTO EXPRESS (CAYMAN) INC. SPONSORED ADR CLASS A
WMT WALMART INC.
ASML ASML HOLDING N.V.
CODX CO-DIAGNOSTICS
KALA KALA PHARMACEUTICALS INC.
BKI BLACK KNIGHT INC.
ZLAB ZAI LAB LTD. SPONSORED ADR
SE SEA ADS
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
CTXS CITRIX SYSTEMS INC.
RHHBY ROCHE HOLDING AG ADS
RCUS ARCUS BIOSCIENCES
BILI BILIBILI INC. SPONSORED ADR CLASS Z
DOCU DOCUSIGN INC.
ZM ZOOM VIDEO COMMUNICATIONS INC. CLASS A
RAD RITE AID CORPORATION
VAPO VAPOTHERM
CLVT CLARIVATE PLC (A)
BJ BJ'S WHOLESALE CLUB HOLDINGS
VIR VIR BIOTECHNOLOGY
GSX GSX TECHEDU INC. SPONSORED ADR CLASS A

ResearchPool Subscriptions

Get the most out of your insights

Get in touch